Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.

doi:10.1038/s41416-024-02649-z

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.

British journal of cancer - 1 May 2024

Rio-Vilariño Anxo, Cenigaonandia-Campillo Aiora, García-Bautista Ana, Mateos-Gómez Pedro A, Schlaepfer Marina I, Del Puerto-Nevado Laura, Aguilera Oscar, García-García Laura, Galeano Carlos, de Miguel Irene, Serrano-López Juana, Baños Natalia, Fernández-Aceñero María Jesús, Lacal Juan Carlos, Medico Enzo, García-Foncillas Jesús, Cebrián Arancha

Abstract excerpt

BACKGROUND: Primary resistance to anti-EGFR therapies affects 40% of metastatic colorectal cancer patients harbouring wild-type RAS/RAF. YAP1 activation is associated with this resistance, prompting an investigation into AURKA's role in mediating YAP1 phosphorylation at Ser397, as observed in breast cancer. METHODS: We used transcriptomic analysis along with in vitro and in vivo models of RAS/RAF wild-type CRC to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aurora Kinase A

Share to Cell Line, Tumor

Share to Cetuximab

Share to Colorectal Neoplasms

Share to Drug Resistance, Neoplasm

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 38467828
DOI: 10.1038/s41416-024-02649-z
PMCID: PMC11014903

Genes

AURKA
YAP1
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.PMID 38467828Read ↗

Basroparib overcomes acquired resistance to MEK inhibitors by inhibiting Wnt-mediated cancer stemness in KRAS-mutated colorectal cancerSemantic proximity Read ↗

RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS status.Semantic proximity Read ↗

Aurka orchestrates colorectal cancer progression through dual regulation of tumor proliferation and immune microenvironmentSemantic proximity Read ↗

MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancerSemantic proximity Read ↗

SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Semantic proximity Read ↗

Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancerSemantic proximity Read ↗

YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis.Semantic proximity Read ↗

Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screeningSemantic proximity Read ↗

Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.Semantic proximity Read ↗

An MST4‐pβ‐CateninThr40 Signaling Axis Controls Intestinal Stem Cell and TumorigenesisSemantic proximity Read ↗

Identification and Validation of Aurora Kinase A (AURKA) Involved in the Progression and Imatinib Resistance of Advanced Gastrointestinal Stromal TumorsSemantic proximity Read ↗

Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.